Finally, the observation that CSTB overexpression only partially reversed the tumour‐suppressive effects of ATRA suggests that ATRA likely exerts its anti‐HCC activity through mechanisms beyond the CSTB/CYTB axis. The gene discussed is MT-CYB; the disease is hepatocellular carcinoma.